Navigation Links
Asia-Pacific Non-Small Cell Lung Cancer Therapeutics Markets to 2023: Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market - Research and Markets
Date:4/8/2017

DUBLIN, Apr. 07, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" report to their offering.

The NSCLC market in Asia-Pacific is forecast to grow substantially, from $3 billion in 2016 to $6.2 billion in 2023, at a compound annual growth rate (CAGR) of 10.8%.

Owing to strong clinical performances, immune-checkpoint inhibitors will have a greater uptake than other second-line market entrants and will compete among themselves for market share in the APAC region. The entry of targeted therapies into the market will offset the effect of patent expiries for drugs such as Avastin, Alimta, and Tarceva, which will have a limited impact on the market between 2016 and 2023.

New targeted and immuno-therapies will drive market growth due to premium pricing and strong clinical performances, but they will also increase the degree of NSCLC market segmentation and the complexity of the treatment algorithm, owing to their enhanced efficacy in specific patient populations. The limited effect of patent expiry on the NSCLC market is one of the main reasons for the substantial growth in value expected in the forecast period, as the introduction of numerous therapies will not be offset by generic erosion; instead, premium therapies will occupy a larger market share for much of the forecast period in APAC.

The rate of mutation testing is very low in China and India compared with Australia, South Korea and Japan, and this makes many patients ineligible to receive targeted therapies. However, it is increasing, driven by increasing awareness among the healthcare fraternity. Hence, targeted therapies are expected to be used more often, driving market growth. Moreover, healthcare access and awareness have improved in India and China due to government initiatives. This will increase the market size by strengthening the treatment pool.
Key Topics Covered:

1 Introduction
1.1 Disease Introduction
1.2 Epidemiology
1.3 Symptoms
1.4 Etiology and Pathophysiology
1.5 Diagnosis
1.6 Prognosis
1.7 Treatment Guidelines and Options

2 Marketed Products
2.1 Overview
2.2 Chemotherapies
2.2.1 Alimta (pemetrexed) - Eli Lilly
2.2.2 Abraxane (paclitaxel) - Celgene
2.3 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
2.3.1 Tarceva (erlotinib) - Roche
2.3.2 Iressa (gefitinib) - AstraZeneca
2.3.3 Gilotrif/Giotrif/Xovoltib (afatinib) - Boehringer Ingelheim
2.3.4 Tagrisso (osimertinib/AZD-9291) - AstraZeneca
2.3.5 Olita (olmutinib) - Hanmi Pharmaceuticals
2.3.6 Conmana (icotinib) - Betta Pharmaceuticals
2.4 Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors
2.4.1 Xalkori (crizotinib) - Pfizer
2.4.2 Alecensa (alectinib) - Roche
2.4.3 Zykadia (ceritinib/LDK378) - Novartis
2.5 Programmed Cell Death Protein 1/Programmed Death Ligand 1 Immune Checkpoint Inhibitors
2.5.1 Opdivo (nivolumab) - Bristol-Myers Squibb
2.5.2 Keytruda (pembrolizumab) - Merck & Co
2.6 Other
2.6.1 Avastin (bevacizumab) - Roche
2.6.2 Cyramza (Ramucirumab) - Eli Lilly
2.6.3 Ofev/Vargatef (Nintedanib) - Boehringer Ingelheim
2.7 Conclusion
2.8 Comparative Efficacy and Safety of Marketed Products

3 Pipeline Analysis
3.1 Overview
3.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
3.3 Pipeline by Molecular Target
3.4 Promising Pipeline Candidates
3.4.1 Yervoy (Ipilimumab) - Bristol-Myers Squibb
3.4.2 Tecentriq (Atezolizumab) - Roche
3.4.3 Necitumumab - Eli Lilly
3.4.4 Durvalumab plus Tremelimumab (MEDI-4736/MEDI-1123) - MedImmune
3.4.5 Veliparib - AbbVie
3.4.6 Vaxira - Recombio
3.4.7 Abemaciclib - Eli Lilly
3.4.8 Dacomitinib - Pfizer
3.4.9 Ensartinib (X-396) - Xcovery
3.4.10 Anlotinib (AL-3818) - Jiangsu Chia-Tai Tianqing
3.4.11 CimaVax-EGF (BVNSCLC-001) - Bioven
3.4.12 Brigatinib (AP-26113) - Ariad Pharmaceuticals
3.4.13 Naquotinib Mesylate (ASP8273) - Astellas Pharma
3.4.14 Plinabulin - BeyondSpring Pharma
3.4.15 Fruquintinib (HMPL-013) - Hutchison MediPharma
3.4.16 Famitinib (SHR-1020) - Jiangsu Hengrui Medicine
3.4.17 Vandetanib (ZD 6474) - Genzyme
3.4.18 Aitan (Apatinib) - Jiangsu Hengrui Medicine
3.5 Comparative Efficacy and Safety of Pipeline Products
3.6 Product Competitiveness Framework

4 Clinical Trial Analysis
4.1 Failure Rate
4.1.1 Overall Failure Rate
4.1.2 Failure Rate by Phase and Molecule Type
4.1.3 Failure Rate by Phase and Molecular Target
4.2 Clinical Trial Size
4.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development
4.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development
4.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development
4.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development
4.3 Clinical Trial Duration
4.3.1 Trial Duration by Molecule Type and Stage of Development
4.3.2 Trial Duration by Molecular Target and Stage of Development
4.4 Summary of Clinical Trial Metrics

5 Multi-scenario Forecast

  • Treatment Usage Patterns
  • Annual Cost of Therapy
  • Market Size

6 Drivers and Barriers
6.1 Drivers
6.1.1 Increasing Pollution and Passive Smoking to Drive the Incidence
6.1.2 Increasing Elderly Population and Incidence of NSCLC
6.1.3 The Availability of Novel First- and Second-Line Therapy Options in Pipeline
6.1.4 Increase in Mutation Testing to Drive Market Growth
6.1.5 Diversified Healthcare Reform to Boost Market Growth
6.1.6 Diversified Health Insurance System to Help Nurture Growth
6.2 Barriers
6.2.1 Patent Expiration of Branded Therapies to Affect NSCLC Market Growth
6.2.2 High Prices of Therapeutics to Slow Down Market Growth
6.2.3 Lack of Reimbursement and Penetration of Generic Drugs to Hinder Market Growth in China and India
6.2.4 Drug Pricing Reforms

7 Deals and Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region and Value
7.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
7.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
7.1.4 Key Licensing Deals
7.2 Co-development Deals
7.2.1 Deals by Region and Value
7.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
7.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
7.2.4 Key Co-development Deals

8 Appendix
8.1 All Pipeline Drugs by Stage of Development
8.1.1 Discovery
8.1.2 Preclinical
8.1.3 Investigational New Drug/Clinical Trial Authorization-Filed
8.1.4 Phase I
8.1.5 Phase II
8.1.6 Phase III
8.1.7 Pre-registration
8.2 Summary of Multi-scenario Market Forecasts to 2023
8.2.1 Asia-Pacific
8.2.2 India
8.2.3 China
8.2.4 Australia
8.2.5 South Korea
8.2.6 Japan
8.3 Bibliography
8.4 Abbreviations

For more information about this report visit http://www.researchandmarkets.com/research/wmv5j4/nonsmall_cell

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/asia-pacific-non-small-cell-lung-cancer-therapeutics-markets-to-2023-launch-of-premium-targeted-therapies-and-increasing-prevalence-to-drive-the-market---research-and-markets-300436582.html


'/>"/>
SOURCE Research and Markets
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Asia-Pacific Mobile C-Arms Market Outlook to 2022
2. Asia-Pacific Bone Densitometers Market Outlook to 2022
3. Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Market to hit $27 Billion by 2022, Despite Low Innovation - Research and Markets
4. Asia-Pacific Cataract Surgery Devices Market Outlook to 2022
5. Asia-Pacific Anti-hypertensive Therapeutics Market will Increase by Almost $8 Billion by 2022, says GBI Research
6. Asia-Pacific Remote Patient Monitoring Market Outlook to 2022
7. Asia-Pacific Neonatal Monitors Market Outlook to 2022
8. Asia-Pacific Multiparameter Patient Monitoring Market Outlook to 2022
9. SIRveNIB, un importante studio sul cancro primario del fegato nella regione Asia-Pacifico, ha completato il reclutamento
10. Biosensors Market in Asia-Pacific is Expected to Grow at 11.5% CAGR During 2016 - 2022: P&S Market Research
11. Insulin Delivery Device Market Expected to Witness the Fastest Growth in Asia-Pacific, During 2016 - 2022: P&S Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... FLINT, Mich. , Oct. 2, 2017 ... acquired 8th Day Software and Consulting, LLC , ... 8th Day Software, based in Tennessee ... Management LLC. 8th Day expands EnvoyHealth,s service offerings for ... product development. "In ...
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and fastest ... to open a flagship location in Covington, LA at 401 N. U.S. Highway 190, ... next to Office Depot in the Holiday Square shopping center. Its location allows it ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health ... Miles by Moonlight to raise money for the American Heart Association Heart Walk. Teams ... Teams will work together to keep their treadmills moving for 5 hours. Treadmills will ...
Breaking Medicine News(10 mins):